Release Date: April 29, 2025

Expiration Date: April 29, 2026

Activity Overview

Although anti-VEGF therapies have advanced the management of nAMD and DME, limitations with their use – including the need for frequent injections – led to the development of newer anti-VEGF agents. In this program, a panel of expert faculty share a roundtable discussion to explore opportunities to educate patients on their treatment options, individualize anti-VEGF treatment intervals, and provide team-based care for these patients.

Target Audience

This online educational activity is directed toward retina specialists, ophthalmologists, and optometrists.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Summarize disease and treatment burden that impact quality of life in nAMD
Outline burden of disease and treatment in DME that impact quality of life
Integrate real-world evidence into the development of individualized treatment plans for the management of nAMD
Utilize evidence regarding advanced dosing strategies to create personalized management plans for patients with DME

Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is accredited by COPE to provide continuing education to optometrists.

Physicians’ Education Resource^®, LLC designates this activity for a maximum of 1.0 COPE credits

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Regeneron Pharmaceuticals.

Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

GET STARTED WITH THIS PROGRAM:

Related Content

The New DED Toolkit: Innovative Therapies Reshaping Dry Eye Management

Searching for Silence: Corneal Sensitivity Testing in NK

Advancing Presbyopia Care: Patient-Centered Strategies for Pharmacologic Management

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence